PMID- 18342647
OWN - NLM
STAT- MEDLINE
DCOM- 20080624
LR  - 20131121
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 77
IP  - 4
DP  - 2008 Apr
TI  - Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral 
      contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a 
      randomized, double-blind, placebo-controlled trial.
PG  - 249-56
LID - 10.1016/j.contraception.2007.11.003 [doi]
AB  - BACKGROUND: A randomized, double-blind, parallel-group study to investigate the 
      efficacy and safety of the 3 mg drospirenone (drsp)/20 mcg ethinylestradiol (EE) 
      combined oral contraceptive (COC) administered in a 24/4 regimen (24 active 
      tablets and 4 inert tablets per cycle) for the treatment of moderate acne 
      vulgaris. STUDY DESIGN: Healthy females (aged 14-45 years old) with moderate 
      facial acne were randomized to 3 mg drsp/20 mcg (n=266) or placebo (n=268) for 
      six cycles of 28 days. RESULTS: Women who received the 3 mg drsp/20 mcg EE 24/4 
      COC had greater reductions from baseline in inflammatory, noninflammatory and 
      total lesion counts. The odds of women in the 3 mg drsp/20 mcg EE 24/4 regimen 
      COC group having 'clear' or 'almost clear' skin as rated by the investigators at 
      end point was about fourfold greater than that in the placebo group (odds ratio 
      4.31; 95% CI: 2.11-9.60; p=.001). The 3 mg drsp/20 mcg EE 24/4 regimen COC was 
      well tolerated and had a safety profile consistent with low-dose COC use. 
      CONCLUSION: The 3 mg drsp/20 mcg EE 24/4 regimen COC was significantly more 
      effective than placebo in treating moderate acne vulgaris.
FAU - Koltun, William
AU  - Koltun W
AD  - Medical Center for Clinical Research, San Diego, CA 92108, USA.
FAU - Lucky, Anne W
AU  - Lucky AW
FAU - Thiboutot, Diane
AU  - Thiboutot D
FAU - Niknian, Minoo
AU  - Niknian M
FAU - Sampson-Landers, Carole
AU  - Sampson-Landers C
FAU - Korner, Paul
AU  - Korner P
FAU - Marr, Joachim
AU  - Marr J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080304
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Androstenes)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - N295J34A25 (drospirenone)
SB  - IM
MH  - Acne Vulgaris/*drug therapy
MH  - Adolescent
MH  - Adult
MH  - Androstenes/*administration & dosage/adverse effects
MH  - Contraceptives, Oral, Combined/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Ethinyl Estradiol/*administration & dosage/adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Treatment Outcome
EDAT- 2008/03/18 09:00
MHDA- 2008/06/25 09:00
CRDT- 2008/03/18 09:00
PHST- 2007/05/28 00:00 [received]
PHST- 2007/11/11 00:00 [revised]
PHST- 2007/11/20 00:00 [accepted]
PHST- 2008/03/18 09:00 [pubmed]
PHST- 2008/06/25 09:00 [medline]
PHST- 2008/03/18 09:00 [entrez]
AID - S0010-7824(07)00500-8 [pii]
AID - 10.1016/j.contraception.2007.11.003 [doi]
PST - ppublish
SO  - Contraception. 2008 Apr;77(4):249-56. doi: 10.1016/j.contraception.2007.11.003. 
      Epub 2008 Mar 4.